Can-Fite BioPharma

Can-Fite initiates development of CF102 for cancer, inflammatory diseases

Published in Pharma Law Weekly, July 25th, 2006

Can-Fite BioPharma (TASE:CFBI) has initiated non-clinical development with its second drug candidate, CF102.

This includes, formulation development, stability testing, metabolism, pharmacokinetics and toxicology studies. Drug substance manufacturing is being scaled to kilogram level to support GLP toxicology and phase I. The data from these studies will enable the company to submit an investigational new drug application (IND) and initiate phase I studies during 2007.

CF102, LIKE CF101, targets a specific cell surface receptor, the A3 adenosine receptor that is known to be over-expressed in tumor and inflammatory cells. CF102 has dual activity...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pharma Law Weekly

Source: Pharma Law Weekly (2006-07-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry